youtube
Eli Lilly delivered impressive second quarter financial results as revenue surged 48 percent year over year to reach 23 billion dollars, outpacing Wall Street expectations by more than 2 billion dollars. The explosive growth was driven primarily by strong demand for its injectable weight loss treatments, pushing first half revenue above 42 billion dollars and surpassing the company's total revenue for the entire year of 2020. While Seeking Alpha Quant ratings maintain a Hold stance due to premium valuation metrics balanced against high growth, Eli Lilly continues to demonstrate strong market momentum backed by an expanding drug pipeline including its next generation blockbuster candidate Retatrutide.
|
